Aevi Genomic Medicine — Medgenics — Q1 2015 Earnings Presentation
17 slides from Aevi Genomic Medicine's earnings presentation, Apr 17, 2015
Slide 1: Q1 2015 Results
Q1 2015 Results April 17, 2015
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results
Slide 3: Agenda
Agenda 3 • Q1 Operational Update • Q1 Financial Update • CHOP Collaboration • 2015 Milestones
Slide 4: Q1 2015 Operational Update
Q1 2015 Operational Update • Low - dose cohort fully enrolled – Positive response to therapy at ~100x lower c max and 10x lower overall exposure vs rHuEPO – Low - dose well tolerated; no treatment related SAE’s • Demonstrated ability to maintain Hb in target range for up to 10 months to date • Initi
Slide 5: MDGN-201 Phase 1/2 Trial Design: TARGT EPO Open Label Ascending Dose
MDGN - 201 (TARGT EPO ) – Open Label Ascending Dose 5 Clinical endpoints: (1) Serum eEPO levels (2) Hb levels (3) Duration (4) Safety Study Summary Group Treatment N A Low dose eEPO 18 - 25 IU/kg/day 3 + 3 * B Mid dose eEPO 35 - 45 IU/kg/day 3 + 3 * C High dose eEPO 55 - 65 IU/kg/day 3 + 3 * MDGN -
Slide 6: Summary Patient Status – Low Dose Cohort
Summary Patient Status – Low Dose Cohort 6 Subject # Age Gender Dialysis (years) Medical History rHuEPO Run - in Dose (IU/ wk ) # of TARGT s Months Post Implant Status E101 70 M 4 hypertension, diabetes 12K 3 10 Ongoing ; s table Hb E102 26 M 0.8 hypertension, IgA nephropathy 12K 2 5 Returned to bas
Slide 7: Potential Orphan Indications for TARGT EPO
Potential Orphan Indications for TARGT EPO 7 INDICATION PATIENT / PAYOR NEED CLINICAL RATIONALE ESTIMATED PREVALENCE PERITONEAL DIALYSIS (PD) PD provides 20% cost reduction vs hemodialysis Improved compliance will boost outcomes and reduce costs for PD patients 20,000 (US) 6 ANEMIC CKD TRANSPLANT CA
Slide 8: CHOP Collaboration
CHOP Collaboration 3 medgenics
Slide 9: "Conventional" Drug Development Process
“Conventional” Drug Development Process 9 10 – 15 Years Timeline with Massive Attrition! New Targets from Literature Animal Models
Slide 10: Genomic Guided Precision Medicine
Genomic Guided Precision Medicine Precision medicine is an emerging approach to disease treatment and prevention based on individual genetic and lifestyle/environmental variation Why now? Cheap and fast genome sequencing Availability of new tools for bioanalytics and large clinical datasets Go
Slide 11: Precision Development Approach
Precision Development A pproach 11 Phenotype (Inherited/Extreme) Tissue Banking Screening/Genomics Hypothesis/Mechanism New “Validated” Target(s)
Slide 12: Precision Drug Development Approach
Precision Drug D evelopment A pproach Phenotype Validated Target & Mechanism Native Peptide/Protein Preclinical POC Enabling Tox Exploratory IND PD Markers Dosing POC Phase IB/II Dose Confirmation Pivotal Trials Submission & Approval 12 12 mos 12 mos 12 mos 12 - 24 mos 12 mos 5 - 6 Yrs
Slide 13: CHOP Medgenics Collaboration Prioritization Criteria
CHOP Medgenics Collaboration Prioritization Criteria • Well characterized and genetically defined rare/orphan disease with clear diagnostic and phenotypic criteria • Serious disease with significant impact on health and/or lifespan of affected individuals • Sufficient characterization of natural his
Slide 14: Collaboration Update
Collaboration Update 14 PARTNER SCOPE KEY DELIVERABLES Harvard University / Massachusetts General Hospital Funding of research program to a ssess the viability of TARGT micro - organs in the CNS Initiated collaboration and anticipate results from initial preclinical experiments mid - year. Stanford
Slide 15: Financial Update
Financial Update ‘8 medgenics
Slide 16: Q1 2015 Financial Update
Q1 2015 Financial Update • Net R&D expenses for the 1 st Quarter were $3.9MM increasing from $2.1MM for the same period in 2014 due mainly to increased materials and sub - contractor costs and increased stock - based compensation expenses related to options granted to R&D personnel . • G&A expenses
Slide 17: 2015 Milestones
2015 Milestones 17 PROGRAM TIMING RENAL ANEMIA Complete enrollment in low dose MDGN - 201 cohort ✓ Initiate enrollment in mid dose MDGN - 201 cohort ✓ Initiate Phase 2 study in Peritoneal Dialysis (PD), including: ✓ - Renal Anemia Transplant patients - ESA Hypo - responsive patients HEMATOLOGICAL DI